{"product_id":"global-monoclonal-antibody-biologics-and-biosimilars-market-growth-status-and-outlook-2023-2029","title":"Global Monoclonal Antibody Biologics and Biosimilars Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Monoclonal Antibody Biologics and Biosimilars Market Growth (Status and Outlook) 2023-2029\u003c\/p\u003e\n\n\u003cp\u003eThe global Monoclonal Antibody Biologics and Biosimilars market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eUnited States market for Monoclonal Antibody Biologics and Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eChina market for Monoclonal Antibody Biologics and Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eEurope market for Monoclonal Antibody Biologics and Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eGlobal key Monoclonal Antibody Biologics and Biosimilars players cover Roche, Amgen, AbbVie, Sanofi, Johnson \u0026amp; Johnson, Pfizer, Eli Lilly, Novartis and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.\u003c\/p\u003e\n\n\u003cp\u003eMonoclonal antibodies are immune system proteins that are created in the lab. Antibodies are produced naturally by your body and help the immune system recognize germs that cause disease, such as bacteria and viruses, and mark them for destruction. Like your body’s own antibodies, monoclonal antibodies recognize specific targets.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Monoclonal Antibody Biologics and Biosimilars Industry Forecast” looks at past sales and reviews total world Monoclonal Antibody Biologics and Biosimilars sales in 2022, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibody Biologics and Biosimilars sales for 2023 through 2029. With Monoclonal Antibody Biologics and Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoclonal Antibody Biologics and Biosimilars industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Monoclonal Antibody Biologics and Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Monoclonal Antibody Biologics and Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Monoclonal Antibody Biologics and Biosimilars market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibody Biologics and Biosimilars and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibody Biologics and Biosimilars.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibody Biologics and Biosimilars market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nBiologics\u003cbr\u003e\nBiosimilars\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nCancer\u003cbr\u003e\nAutoimmune Disease\u003cbr\u003e\nOther\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nRoche\u003cbr\u003e\nAmgen\u003cbr\u003e\nAbbVie\u003cbr\u003e\nSanofi\u003cbr\u003e\nJohnson \u0026amp; Johnson\u003cbr\u003e\nPfizer\u003cbr\u003e\nEli Lilly\u003cbr\u003e\nNovartis\u003cbr\u003e\nMerck\u003cbr\u003e\nBiogen\u003cbr\u003e\nCelltrion\u003cbr\u003e\nSobi\u003cbr\u003e\n3SBIO\u003cbr\u003e\nInnovent Biologics\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"March, 2023 \/ 103 Pages \/ MCW16228862","offer_id":47646892425522,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-monoclonal-antibody-biologics-and-biosimilars-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}